AI Generated Image
3-Year-Old Boy's Cancer Disappears After He Gets Experimental Immunotherapy
Gizmodo • • health
Key Points:
- A 3-year-old boy with advanced, chemotherapy-resistant liver cancer achieved complete remission after receiving an experimental CAR T cell immunotherapy, with the remission lasting at least one year.
- The novel CAR T therapy targets glypican-3, a protein found on cancerous liver cells, and is engineered to express interleukin-15 and interleukin-21 to enhance cancer-fighting potency and cell survival.
- The treatment was well-tolerated, with no serious side effects such as cytokine release syndrome, which is a common risk in CAR T therapies.
- This case is part of an ongoing phase I CARE study at Baylor College of Medicine aiming to enroll 18-30 patients, with results expected by next summer, highlighting potential new options for treating solid tumors like hepatoblastoma.
- The success suggests that CAR T therapy could be extended beyond blood cancers to solid tumors, representing a promising advancement in cancer immunotherapy.
